HMRlignans (Norway spruce extract)

HMRlignan is a purified plant lignan derived from Norway spruce (Picea abies) knots, with 7-hydroxymatairesinol (HMR) as its primary bioactive compound. HMR is converted by gut microbiota into enterolactone, a mammalian lignan that modulates estrogen receptor signaling and may support hormone balance.

Origin & History

HMRlignans is a branded extract of 7-hydroxymatairesinol (HMR), a plant lignan sourced from the wood knots of Norway spruce (Picea abies). It is extracted to yield a high concentration of HMR in aglycone form, co-crystallized with potassium acetate (NLT 90% 7-HMR co-crystal), and belongs to the secoisolariciresinol-type lignan chemical class.

Historical & Cultural Context

Isolated HMRlignan lacks historical traditional use, as it is a modern nutraceutical discovered in the 1990s-2000s from Norway spruce knots. While HMR itself is newly isolated, lignan-rich plants like flaxseed, sesame, and whole grains have been part of traditional diets across cultures for reproductive health, digestive balance, and cardiovascular wellness.

Health Benefits

• Anticancer properties: Preclinical studies in rats showed HMR reduced induced tumor volume, stabilized established tumors, and prevented new tumor formation (animal evidence only)
• Immunomodulation: In vitro studies on THP-1 monocytes and human PMNs demonstrated immunomodulatory activity (PMID: 20005303, cell culture evidence)
• Antioxidant effects: Exhibits antioxidant properties in preclinical models (preliminary evidence)
• Hormone balance: Functions as a weak phytoestrogen with protective rather than stimulatory effects (mechanistic evidence only)
• Potential cardiovascular support: May help lower LDL cholesterol based on mechanism of action studies (theoretical benefit)

How It Works

HMRlignan's primary bioactive, 7-hydroxymatairesinol (HMR), is metabolized by intestinal bacteria—particularly Clostridium scindens and related species—into enterolactone, a phytoestrogen that competes with endogenous estradiol at estrogen receptor alpha (ERα) and beta (ERβ), with preferential affinity for ERβ. Enterolactone also inhibits aromatase (CYP19A1) activity, reducing local estrogen biosynthesis in peripheral tissues. Additionally, HMR and its metabolites modulate NF-κB signaling pathways, suppressing pro-inflammatory cytokine production including TNF-α and IL-6 in monocyte and neutrophil cell lines.

Scientific Research

Limited human clinical trials are available, with most evidence stemming from preclinical studies. One rat study showed antitumor effects including reduced tumor volume and prevention of new tumors, while in vitro research demonstrated immunomodulatory activity in human monocytes and PMNs (PMID: 20005303). No meta-analyses or large-scale human RCTs were identified in the available research.

Clinical Summary

Preclinical rodent studies demonstrated that oral HMR administration reduced chemically-induced mammary tumor volume, stabilized established tumors, and inhibited new tumor formation, though these findings have not been replicated in human clinical trials. In vitro studies using THP-1 monocytes and human polymorphonuclear neutrophils (PMNs) confirmed immunomodulatory activity at the cellular level. Human pharmacokinetic studies have established that dietary HMR reliably elevates serum enterolactone concentrations, with bioavailability dependent on gut microbiome composition. Overall, the current evidence base is preliminary—dominated by animal and cell culture data—and robust randomized controlled trials in humans are lacking.

Nutritional Profile

{"macronutrients": {"fiber": "Not specified", "protein": "Not specified"}, "micronutrients": {"vitamins": "Not specified", "minerals": "Not specified"}, "bioactive_compounds": {"HMR lignans": "Concentration not specified"}, "bioavailability_notes": "Bioavailability of HMR lignans in humans is not well-documented; most evidence is from animal and in vitro studies."}

Preparation & Dosage

No clinically studied human dosage ranges are detailed in the available research. Commercial forms include off-white crystalline powder or capsules/softgels, standardized to NLT 90% 7-HMR co-crystal with potassium acetate. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Probiotics, Green tea extract, Vitamin D3, DIM (diindolylmethane), Calcium D-glucarate

Safety & Interactions

HMRlignan is generally considered well tolerated at studied doses (50–150 mg/day), with no significant adverse effects reported in short-term human pharmacokinetic studies. Due to its estrogenic and anti-estrogenic activity via ERα and ERβ modulation, HMRlignan should be used with caution in individuals with hormone-sensitive conditions such as estrogen receptor-positive breast cancer, uterine fibroids, or endometriosis. Potential interactions exist with tamoxifen, aromatase inhibitors, and other hormone therapies, as the combined estrogenic modulation could alter therapeutic outcomes unpredictably. Safety data during pregnancy and lactation are insufficient, and use is not recommended in these populations.